Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Expert opinion on drug metabolism & toxicology - 1 Aug 2016

Kourie Hampig Raphael, Chaix Marie, Gombos Andrea, Aftimos Phillippe, Awada Ahmad

Abstract excerpt

INTRODUCTION: Despite the availability of several potent HER2-directed targeted agents, primary and acquired resistance continues to influence patient outcomes in HER2-positive breast cancer. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor in late-phase clinical development. AREAS COVERED: This review article focuses on neratinib in the treatment of HER2-positive breast cancer - early and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Resistance, Neoplasm

Share to Protein Kinase Inhibitors

Share to Quinolines

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 27284682
DOI: 10.1080/17425255.2016.1198317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.PMID 27284682Read ↗

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.Semantic proximity Read ↗

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Semantic proximity Read ↗

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.Semantic proximity Read ↗

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.Semantic proximity Read ↗

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.Semantic proximity Read ↗

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.Semantic proximity Read ↗

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.Semantic proximity Read ↗

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read ↗

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4Semantic proximity Read ↗

Peptidylarginine Deiminase 3 Modulates Response to Neratinib in HER2 Positive Breast CancerSemantic proximity Read ↗

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsSemantic proximity Read ↗

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.